EQRx, Inc. (NASDAQ:EQRX – Get Rating) traded down 10% on Thursday . The company traded as low as $4.84 and last traded at $4.84. 45,638 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 1,836,906 shares. The stock had previously closed at $5.38.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on EQRX. The Goldman Sachs Group assumed coverage on shares of EQRx in a research note on Monday, June 13th. They set a "buy" rating and a $8.00 price objective on the stock. JPMorgan Chase & Co. began coverage on EQRx in a research note on Tuesday, August 16th. They set a "neutral" rating and a $5.50 target price for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $6.37.
Get
EQRx alerts:
EQRx Stock Down 11.5 %
The business's 50 day moving average is $5.10 and its 200-day moving average is $4.60.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the company. Advisor Group Holdings Inc. acquired a new stake in shares of EQRx during the 4th quarter valued at approximately $67,000. TD Asset Management Inc. bought a new position in EQRx in the 4th quarter worth about $1,209,000. Qube Research & Technologies Ltd acquired a new stake in shares of EQRx in the fourth quarter valued at approximately $1,951,000. MYDA Advisors LLC acquired a new position in shares of EQRx during the fourth quarter worth approximately $136,000. Finally, Casdin Capital LLC bought a new position in EQRx in the 4th quarter worth approximately $269,579,000. Institutional investors own 80.38% of the company's stock.
EQRx Company Profile
(Get Rating)
EQRx, Inc, a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC.
Featured Stories
- Get a free copy of the StockNews.com research report on EQRx (EQRX)
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 2 Reasons Netflix Might Have Just Bottomed Out
- Murphy USA Outperforming Other Mid-caps, But Is It A Buy Now?
Receive News & Ratings for EQRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EQRx and related companies with MarketBeat.com's FREE daily email newsletter.
EQRx, Inc. (NASDAQ:EQRX – Get Rating) traded down 10% on Thursday . The company traded as low as $4.84 and last traded at $4.84. 45,638 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 1,836,906 shares. The stock had previously closed at $5.38.
納斯達克(EQRX-GET Rating)週四股價下跌10%。該公司股價低至4.84美元，最新報4.84美元。午盤成交量為45,638股，較1,836,906股的平均成交量下降98%。該股此前收盤價為5.38美元。
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on EQRX. The Goldman Sachs Group assumed coverage on shares of EQRx in a research note on Monday, June 13th. They set a "buy" rating and a $8.00 price objective on the stock. JPMorgan Chase & Co. began coverage on EQRx in a research note on Tuesday, August 16th. They set a "neutral" rating and a $5.50 target price for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $6.37.
一些研究公司最近發佈了關於EQRX的報告。高盛在6月13日星期一的一份研究報告中對EQRx的股票進行了報道。他們為該股設定了“買入”評級和8.00美元的目標價。摩根大通公司在8月16日星期二的一份研究報告中開始對EQRx進行報道。他們為該公司設定了“中性”評級和5.5美元的目標價。一名分析師對該股的評級為持有，四名分析師對該公司股票的評級為買入。根據MarketBeat的數據，該公司目前的共識評級為“適度買入”，共識目標價為6.37美元。
Get
EQRx
alerts:
EQRx Stock Down 11.5 %
The business's 50 day moving average is $5.10 and its 200-day moving average is $4.60.
該業務的50日移動均線切入位在5.10美元，200日移動均線切入位在4.60美元。
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the company. Advisor Group Holdings Inc. acquired a new stake in shares of EQRx during the 4th quarter valued at approximately $67,000. TD Asset Management Inc. bought a new position in EQRx in the 4th quarter worth about $1,209,000. Qube Research & Technologies Ltd acquired a new stake in shares of EQRx in the fourth quarter valued at approximately $1,951,000. MYDA Advisors LLC acquired a new position in shares of EQRx during the fourth quarter worth approximately $136,000. Finally, Casdin Capital LLC bought a new position in EQRx in the 4th quarter worth approximately $269,579,000. Institutional investors own 80.38% of the company's stock.
一些大型投資者最近買賣了該公司的股票。Advisor Group Holdings Inc.在第四季度收購了EQRx的新股份，價值約6.7萬美元。道明資產管理公司(TD Asset Management Inc.)在第四季度購買了價值約1,209,000美元的EQRx新頭寸。Qube Research&Technologies Ltd在第四季度收購了EQRx的新股份，價值約為1,951,000美元。MYDA Advisors LLC在第四季度收購了價值約13.6萬美元的EQRx股票的新頭寸。最後，Casdin Capital LLC在第四季度購買了EQRx的一個新頭寸，價值約269,579,000美元。機構投資者持有該公司80.38%的股票。
EQRx Company Profile
EQRx, Inc, a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC.
EQRx，Inc.是一家制藥公司，致力於開發主要用於治療美國腫瘤學和免疫性炎症性疾病的藥物。該公司第三階段臨牀試驗的預註冊計劃包括用於治療表皮生長因子受體(EGFR)突變的非小細胞肺癌(NSCLC)患者的表皮生長因子受體(EGFR)抑制劑Aumoltinib和用於治療第三階段和第四階段非小細胞肺癌(NSCLC)的抗程序性死亡配體1抗體Sugyalimab。
Featured Stories
- Get a free copy of the StockNews.com research report on EQRx (EQRX)
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 2 Reasons Netflix Might Have Just Bottomed Out
- Murphy USA Outperforming Other Mid-caps, But Is It A Buy Now?
- 在EQRX(EQRX)上免費獲取StockNews.com研究報告的副本
- 為什麼醫療產品製造商Repligen可能成為潛在收購對象
- 在10%的水平上，Arbor Realty Trust的股息值得嗎？
- 投資者應關注RF Industries
- Netflix可能剛剛觸底的兩個原因
- 墨菲美國的表現好於其他中型股，但它現在值得嗎？
Receive News & Ratings for EQRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EQRx and related companies with MarketBeat.com's FREE daily email newsletter.
接收EQRx日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對EQRx和相關公司的最新新聞和分析師評級的每日簡要摘要。
